Marksans Pharma Limited (NSE: MARKSANS)
India
· Delayed Price · Currency is INR 308.65
-0.50 (-0.16%)
Nov 22, 2024, 3:29 PM IST
Marksans Pharma Revenue
Marksans Pharma had revenue of 6.42B INR in the quarter ending September 30, 2024, with 20.84% growth. This brings the company's revenue in the last twelve months to 23.79B, up 19.11% year-over-year. In the fiscal year ending March 31, 2024, Marksans Pharma had annual revenue of 21.77B with 17.56% growth.
Revenue (ttm)
23.79B
Revenue Growth
+19.11%
P/S Ratio
5.88
Revenue / Employee
20.85M
Employees
1,141
Market Cap
139.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 21.77B | 3.25B | 17.56% |
| Mar 31, 2023 | 18.52B | 3.61B | 24.23% |
| Mar 31, 2022 | 14.91B | 1.15B | 8.33% |
| Mar 31, 2021 | 13.76B | 2.42B | 21.32% |
| Mar 31, 2020 | 11.34B | 1.34B | 13.43% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMarksans Pharma News
- 9 days ago - Marksans Pharma Ltd (BOM:524404) Q2 FY25 Earnings Call Highlights: Strong Revenue Growth and ... - GuruFocus
- 11 days ago - Marksans Pharma shares jump over 3% on Q2 results - Business Upturn
- 11 days ago - Marksans Pharma Q2 FY25: Revenue up 20.84% YoY to Rs 641.92 crore, Net Profit up 16.56% YoY - Business Upturn
- 11 days ago - Marksans Pharma Q2 FY25 results: Stock surge over 3% ahead of result announcement - Business Upturn